MarketPulse

Phase 3 clinical trial failure

1 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Ultragenyx Faces Class Action Over Failed Drug Trials; Investors Have Until April 6 Deadline

Ultragenyx ($RARE) faces class action lawsuit over failed setrusumab Phase 3 trials, with stock down 42%. Investors have until April 6, 2026 to seek lead plaintiff status.
RAREsecurities fraudclass action lawsuit